Floatz Rating
C39/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Fujian Medical University
Modality
Small molecule
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fibrotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dota-Fapi-04 Gallium Ga-68 (this asset) | First Affiliated Hospital of Fujian Medical University | Early P1 | C · 39 |
| Entecavir | Tanta University | P4 | BB |
| Peg-Intron | Beth Israel Deaconess Medical Center | P4 | BB |
| Colchicinum | Zagazig University | P4 | BB |
| Peg-Ifn | Beijing Friendship Hospital | P4 | BB |
| Ribavirin | ANRS, Emerging Infectious Diseases | P3 | BB |
| A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness | Bristol-Myers Squibb | P2 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
| Losartan | Hospital Clinic of Barcelona | P4 | BB |
+42 more in the Fibrotic Liver Disease cohort
Other indications for Dota-Fapi-04 Gallium Ga-68
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | N/A | D · 30 |
| Breast Cancer | — | N/A | D · 26 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dota-Fapi-04 Gallium Ga-68 in Fibrotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dota-fapi-04-gallium-ga-68-fibrotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →